Repligen Corporation (RGEN) reported second-quarter 2026 revenue of $204 million, up 12% year over year as reported and 13% on an organic basis. GAAP net income was $5.0 million, compared with $14.9 million a year earlier, and diluted EPS was $0.09, compared with $0.26.
The company raised its full-year 2026 organic revenue growth guidance to 10.5% to 13.5% and adjusted diluted EPS guidance to $2.03 to $2.09. Repligen also highlighted its definitive agreement to acquire BioLife Solutions and the opening of a new training and innovation center in Breda, the Netherlands.
- Q2 2026 total revenue was $204.1 million, compared with $182.4 million in Q2 2025.
- GAAP income from operations was $14.0 million, compared with $13.9 million a year earlier.
- GAAP net income margin was 2.5%, compared with 8.2% in the prior-year quarter.
- Cash, cash equivalents and marketable securities were $810 million at June 30, 2026.
- Full-year 2026 total reported revenue guidance is $813 million to $835 million.
